Chemotherapy-Induced Febrile Neutropenia

FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.

Also Known As:

Drug-Induced Febrile Neutropenia; Chemotherapy Induced Febrile Neutropenia; Chemotherapy-Induced Febrile Neutropenias; Drug Induced Febrile Neutropenia; Drug-Induced Febrile Neutropenias; Febrile Neutropenia, Chemotherapy-Induced; Febrile Neutropenia, Drug-Induced; Febrile Neutropenias, Chemotherapy-Induced; Febrile Neutropenias, Drug-Induced; Neutropenia, Chemotherapy-Induced Febrile; Neutropenia, Drug-Induced Febrile; Neutropenias, Chemotherapy-Induced Febrile; Neutropenias, Drug-Induced Febrile

Networked: 124 relevant articles (7 outcomes, 29 trials/studies)

Relationship Network

Disease Context: Research Results

Hemic and Lymphatic Diseases: 6
- Hematologic Diseases: 3366
  - Cytopenia: 2582
    - Leukopenia: 5826
      - Agranulocytosis: 4051
        Neutropenia: 16591
        Febrile Neutropenia: 3912
        Chemotherapy-Induced Febrile Neutropenia: 124
  - Leukocyte Disorders: 8
    - Leukopenia: 5826
      - Agranulocytosis: 4051
        Neutropenia: 16591
        Febrile Neutropenia: 3912
        Chemotherapy-Induced Febrile Neutropenia: 124

Related Diseases

1.	Neoplasms (Cancer)
2.	Breast Neoplasms (Breast Cancer)
3.	Hematologic Neoplasms (Hematological Malignancy)
4.	Lymphoma (Lymphomas)
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer)

Experts

1.	Abraham, Ivo: 14 articles (06/2022 - 03/2011)
2.	MacDonald, Karen: 12 articles (01/2021 - 03/2011)
3.	Aapro, Matti: 10 articles (06/2019 - 05/2010)
4.	Weycker, Derek: 9 articles (04/2021 - 02/2013)
5.	Gascón, Pere: 7 articles (06/2019 - 03/2011)
6.	McBride, Ali: 6 articles (06/2022 - 10/2017)
7.	Bensink, Mark: 6 articles (01/2021 - 12/2017)
8.	Ludwig, Heinz: 6 articles (06/2019 - 03/2011)
9.	Boccadoro, Mario: 5 articles (06/2019 - 01/2016)
10.	Bokemeyer, Carsten: 5 articles (06/2019 - 01/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chemotherapy-Induced Febrile Neutropenia:

1.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 09/01/2023 - "Inpatients diagnosed with chemotherapy-induced febrile neutropenia, older than the age of 18 years, and treated with granulocyte colony-stimulating factor were included in the study. " 01/01/2021 - "The main objective of this study is to evaluate the usage of absolute monocyte count (AMC) at presentation as a prognostic factor for patients with chemotherapy-induced febrile neutropenia who were subsequently treated with granulocyte colony-stimulating factor (G-CSF). " 01/01/1994 - " Results of 1 trial show equivalent cost savings of 40% versus placebo with either rGM-CSF or recombinant granulocyte colony-stimulating factor (rG-CSF) in patients with chemotherapy-induced febrile neutropenia. " 02/01/2023 - "Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis." 10/24/2022 - "Materials and Methods: The electronic medical records at our center were utilized to identify patients with a first attack of chemotherapy-induced febrile neutropenia and were treated accordingly with G-CSF between January 2010 to December 2020. "
2.	Anti-Bacterial Agents (Antibiotics)IBA 10/30/2014 - "The use of a CSF plus antibiotics in individuals with chemotherapy-induced febrile neutropenia had no effect on overall mortality, but reduced the amount of time participants spent in hospital and improved their ability to achieve neutrophil recovery. " 10/30/2014 - "We searched for randomized controlled trials (RCTs) that compared CSF plus antibiotics versus antibiotics alone for the treatment of chemotherapy-induced febrile neutropenia in adults and children. " 07/01/2021 - "Using a combination of antibiotics is warranted in patients presenting with chemotherapy-induced febrile neutropenia." 07/01/2021 - "Patterns of Bacterial Isolates and their Resistance to Antibiotics in Patients with Chemotherapy-induced Febrile Neutropenia at a University Hospital." 11/01/2020 - "To use Lean Six Sigma methodology, a quality improvement initiative, to improve time to antibiotics (TTA) for children with chemotherapy-induced febrile neutropenia presenting to the emergency department. "
3.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/01/2004 - "Three placebo-controlled trials showed that GM-CSF was ineffective in reducing the risk of chemotherapy-induced febrile neutropenia. " 03/01/1998 - "GM-CSF in chemotherapy-induced febrile neutropenia--a double-blind randomized study." 10/01/2004 - "A systematic review assessing the efficacy of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced febrile neutropenia and related complications was performed. " 10/01/2004 - "Unlike granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) is not approved for reducing the incidence or duration of chemotherapy-induced febrile neutropenia. " 10/01/2006 - "The uses of the recombinant human hematopoietic colony-stimulating factors G-CSF and GM-CSF for treatment and prophylaxis of chemotherapy-induced febrile neutropenia will be reviewed here."
4.	Filgrastim (Neupogen)FDA Link 12/01/2022 - "This study aimed to compare the effectiveness and safety of filgrastim and filgrastim-aafi for the primary prophylaxis of chemotherapy induced-febrile neutropenia in the real-life setting. " 12/01/2022 - "Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study." 01/01/2018 - "Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia." 10/01/1994 - "Filgrastim in patients with chemotherapy-induced febrile neutropenia. " 06/01/2019 - "Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study."
5.	pegfilgrastim (Neulasta)FDA Link 10/01/2022 - "Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study." 10/01/2023 - "Pegfilgrastim is indicated to decrease the incidence of chemotherapy-induced febrile neutropenia. " 01/01/2019 - "Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims." 01/01/2018 - "Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims." 12/01/2017 - "Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015."
6.	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 07/01/1998 - "A study was performed in low-risk cancer patients with chemotherapy-induced febrile neutropenia to determine the safety and efficacy of ceftriaxone given in an outpatient setting. "
7.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/01/2023 - "Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis."
8.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/01/2023 - "Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis."
9.	Moxifloxacin (Avelox)FDA Link 04/01/2013 - "In this retrospective study, we compared the prophylactic efficacy of moxifloxacin (MFLX) and tosufloxacin (TFLX) for chemotherapy-induced febrile neutropenia. " 04/01/2013 - "Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies."
10.	tosufloxacinIBA 04/01/2013 - "In this retrospective study, we compared the prophylactic efficacy of moxifloxacin (MFLX) and tosufloxacin (TFLX) for chemotherapy-induced febrile neutropenia. " 04/01/2013 - "Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 11/01/2022 - "Chemotherapy-induced febrile neutropenia (FN) is a life-threatening and chemotherapy dose-limiting adverse event. " 11/20/2021 - "Patients treated with chemotherapy are at risk of developing chemotherapy-induced febrile neutropenia (FN), a potentially life-threatening complication. " 01/01/2017 - "Myelotoxic chemotherapy is associated with chemotherapy-induced (febrile) neutropenia (CIN/FN). " 09/01/2014 - "Chemotherapy-induced febrile neutropenia (FN) is a clinically important complication that affects patient outcome by delaying chemotherapy doses or reducing dose intensity. " 01/01/2023 - "Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that may occur in patients with malignancies receiving myelosuppressive chemotherapy. "
2.	Therapeutics 07/01/2012 - "A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children." 01/01/2012 - "The role of risk stratification of chemotherapy-induced febrile neutropenia patients continues to evolve as the practice of risk-based therapy has been demonstrated to be beneficial to patients, clinicians and health care organisations. " 01/01/1994 - " Thus, at present rGM-CSF therapy appears to offer a means of reducing hospitalisation costs, and therefore a substantial component of treatment expenditure, in patients undergoing ABMT or with chemotherapy-induced febrile neutropenia." 01/01/2003 - "Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy." 10/24/2022 - "Herein we present a retrospective risk factor identification study to evaluate the prognostic role of lymphocyte-based measures and ratios in a cohort of chemotherapy-induced febrile neutropenia patients following granulocyte colony-stimulating factor (G-CSF) therapy. "
3.	Drug Tapering 06/01/2013 - "Chemotherapy-induced febrile neutropenia(FN)is a major risk factor for severe infections, with a dose-limiting toxicity that necessitates dose reductions and/or delays in scheduled chemotherapy sessions. " 11/01/2011 - "Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. " 10/01/2013 - "Chemotherapy-induced febrile neutropenia (FEN), which causes treatment delays or chemotherapy dose reductions, is a serious side effect of cancer treatment. " 09/01/2023 - "The outcomes related to chemotherapy-induced febrile neutropenia were chemotherapy dose reduction (31%), chemotherapy cycle delays (21%), chemotherapy treatment suspension (17%), deaths (7%), and other associated complications (10%). "
4.	Treatment Delay 11/01/2017 - "Chemotherapy-induced febrile neutropenia (FN) causes treatment delays and interruptions and can have fatal consequences. " 10/01/2013 - "Chemotherapy-induced febrile neutropenia (FEN), which causes treatment delays or chemotherapy dose reductions, is a serious side effect of cancer treatment. "
5.	Transjugular Intrahepatic Portasystemic Shunt 06/01/2013 - "[Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia]."